ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Treatment for Rare Blood Disease
November 16, 2021Today, the U.S. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells. -
PharmaEssentia resubmits BLA for polycythemia vera therapeutic
May 18, 2021US subsidiary of Taiwan, China-based PharmaEssentia has resubmitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) to obtain approval for ropeginterferon alfa-2b-njft for polycythemia vera (PV) treatment. -
Protagonist Announces Phase 2 Results for Polycythemia Vera Treatment
May 13, 2020Protagonist Therapeutics announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera.
Pharma Sources Insight January 2025
